Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above

NCT07481604 is registered in ClinicalTrials.gov with Aribio Lab Co., Ltd. as lead sponsor.

NCT NCT07481604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07481604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
Lead sponsor
Aribio Lab Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
January 31, 2027
Enrollment
135 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster